Wilke, Marieke R.
Broschmann, Daniel
Sandek, Anja
Wachter, Rolf
Edelmann, Frank
Herrmann-Lingen, Christoph
Funding for this research was provided by:
Project DEAL
Federal Ministry of Education and Research Grant (01GI0205, 01GI0205, 01GI0205)
Georg-August-Universität Göttingen
Article History
Received: 22 April 2022
Accepted: 20 February 2023
First Online: 5 April 2023
Declarations
:
: The Aldo-DHF trial has been conducted in accordance with national laws and ICH guidelines for good clinical practice issued in June 1996 and CPMP/ICH/135/95 from September 1997, taking into account the Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001. All persons participating in the conduct of the trial committed themselves to consider the Declaration of Helsinki and all its revisions (including the Edinburgh Amendment from October 2000). The study protocol was approved by the Ethics Committee of the University of Göttingen Medical Center (#6/12/06) and all participating sites, i.e. the Ethics Committees at the Universities of Berlin (#566/06), Cologne (#06–229), and Würzburg (#179/06), and the Medical Associations of Hamburg (#M-311–06) and Munich (#411–06).
: Not applicable.
: CHL is receiving royalties from Hogrefe Huber Publishers, Berne, for the German version of the Hospital Anxiety and Depression Scale. Over the past 3 years, he has been receiving lecture honoraria from Servier and Novartis. RW reports personal fees from Bayer, grants and personal fees from Boehringer Ingelheim, personal fees from Pfizer/BMS, other from Daiichi Sankyo, personal fees from Novartis, personal fees from Sanofi, personal fees from Servier, grants and personal fees from Medtronic, personal fees from Pharmacosmos, personal fees from CVRx, grants from German Federal Ministry for Education and Research, and grants from DFG, outside the submitted work. AS is receiving grants from the Oskar-Helene-Heim Foundation. MW, DB and FE report no competing interest.